• Consult an expert when treating pregnant women with DR-TB
• Start treatment of drug-resistant TB in second trimester or sooner if patient’s condition is severe
• Avoid injectable agents (if this can be done while providing the pregnant patient an acceptable regimen)
• Avoid ethionamide
• Pregnant patients should be carefully evaluated, taking into consideration gestational age and severity of the drug- resistant TB.
• The risks and benefits of treatment should be carefully considered, with the primary goal of smear conversion to protect the health of the mother and child, both before and after birth.

For both TB and MDR-TB, as long as the mother is smear-negative and on appropriate treatment, the infant may remain with her after delivery.